title: Prevalence of HOXB13 mutation in a population of Ashkenazi Jewish men treated for prostate cancer.
abstract: We performed a retrospective analysis of germline DNA samples from Ashkenazi Jewish men and a comparison group of non-Ashkenazi men treated for prostate cancer at our institution to determine the prevalence of HOXB13 G84E mutation in prostate cancer patients of Ashkenazi Jewish heritage, an ethnic group common to the New York City area. Patients were genotyped for G84E using a TaqMan assay (Applied Biosystems). Positive cases were confirmed using Sanger sequencing. Median age at prostate cancer diagnosis was 68 years for 889 Ashkenazi Jewish patients, 64 years for 920 non-Ashkenazi Jewish patients. The median follow up was 9 years for Ashkenazi Jewish patients and 8.8 years for non-Ashkenazi Jewish patients. Only 4 patients were found to be heterozygous carriers of G84E. They were all of non-Ashkenazi Jewish ancestry and were diagnosed at 70, 66, 78, and 49 years of age. Two of them presented with high-risk prostate cancer. The prevalence of G84E in the non-Ashkenazi sample was 0.4%. HOXB13 G84E mutation was not observed in prostate cancer patients of Ashkenazi Jewish ancestry treated at our institution. Screening for G84E, therefore, may be unnecessary in Ashkenazi Jewish men if these results are validated by other studies.
authors.affiliation: Department of Surgery, Urology Service, and Department of Medicine, Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: Shaheen
authors.initials: S
authors.lastname: Alanee
authors.forename: Sohela
authors.initials: S
authors.lastname: Shah
authors.forename: Joseph
authors.initials: J
authors.lastname: Vijai
authors.forename: Kasmintan
authors.initials: K
authors.lastname: Schrader
authors.forename: Robert
authors.initials: R
authors.lastname: Hamilton
authors.forename: Rohini
authors.initials: R
authors.lastname: Rau-Murthy
authors.forename: Kara
authors.initials: K
authors.lastname: Sarrel
authors.forename: Christopher
authors.initials: C
authors.lastname: Manschreck
authors.forename: James
authors.initials: J
authors.lastname: Eastham
authors.forename: Kenneth
authors.initials: K
authors.lastname: Offit
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D018398:Homeodomain Proteins / Q000235:genetics*; D006801:Humans; D007585:Jews; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009518:New York / Q000453:epidemiology; D015995:Prevalence; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000235:genetics* / Q000628:therapy
chemical_list: C484414:HOXB13 protein, human; D018398:Homeodomain Proteins